NASDAQ:MEDP - Medpace Stock Price, Price Target & More

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings data on Monday, April, 30th. The company reported $0.60 EPS for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.17. The firm earned $108.40 million during the quarter, compared to analysts' expectations of $113.12 million. Medpace had a net margin of 10.37% and a return on equity of 12.50%. The company's revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 earnings per share. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Medpace.

Medpace updated its FY18 earnings guidance on Monday, April, 30th. The company provided earnings per share guidance of $1.87-1.97 for the period, compared to the Thomson Reuters consensus estimate of $1.88. The company issued revenue guidance of $421-435 million, compared to the consensus revenue estimate of $463.04 million.

8 Wall Street analysts have issued 1-year price targets for Medpace's shares. Their forecasts range from $35.00 to $42.00. On average, they expect Medpace's share price to reach $37.40 in the next year. This suggests that the stock has a possible downside of 22.1%. View Analyst Ratings for Medpace.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Medpace include PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI) and Luna Innovations (LUNA).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Media coverage about MEDP stock has trended positive on Monday, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medpace earned a daily sentiment score of 0.35 on Accern's scale. They also gave news coverage about the company an impact score of 45.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Medpace's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER LTD (37.70%) and Fisher Asset Management LLC (0.28%). Company insiders that own Medpace stock include August J Troendle, Medpace Limited Partnership and Susan E Burwig. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $47.98.

Medpace has a market capitalization of $1.70 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]